Previous 10 | Next 10 |
Compugen (NASDAQ: CGEN ) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket. More news on: Compugen Ltd., Incyte Corporation, NextCure, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
NextCure (NASDAQ: NXTC ): FY GAAP EPS of -$2.15 misses by $0.12 . More news on: NextCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BELTSVILLE, Md., March 12, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter an...
The following slide deck was published by NextCure, Inc. in conjunction with this Read more ...
BELTSVILLE, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will pres...
BELTSVILLE, Md., Feb. 18, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will pres...
Quietly on Jan. 13, Nextcure (NASDAQ: NXTC) filed a terse 8-K with the SEC stating that Eli Lilly (NYSE: LLY) was terminating a research and development pact forged in November 2018. Nextcure's stock righted itself after a brief sell-off the morning after the filing. Image source:...
BELTSVILLE, Md., Jan. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company ...
Welcome to a special New Year's Day edition of Seeking Alpha's Stocks to Watch series - a preview of some key events and catalysts to look for in the new year. A podcast of Stocks to Watch is available every Sunday on Seeking Alpha , Apple Podcasts , Stitcher and Spotify (click the highl...
Investing in IPO stocks can be fun, but also risky. There can be a scarcity of information about a brand new equity. And sometimes the underwriters intentionally lowball the value of a company, in order to hype the stock (and reward the bank's clients who bought shares on the cheap). None...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...